跳至主要内容
临床试验/NL-OMON26386
NL-OMON26386招募中不适用

A prospective single-centre study on the efficacy and safety of 4 weekly pasireotide LAR administration in combination with or without weekly pegvisomant in previously controlled acromegaly subjects with combined treatment of long-acting somatostatin analogues and weekly pegvisomant.

Erasmus University Medical Center Rotterdam0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Written informed consent male or female aged ≥ 18 years
  • - Documentation supporting the diagnosis of acromegaly based on elevated GH and/or IGF-I levels due to a pituitary tumor

排除标准

  • - Has undergone pituitary surgery or radiotherapy within 6 months prior to study entry.

研究者

发起方
Erasmus University Medical Center Rotterdam

相似试验